Výsledky vyhledávání - "ULRICH DUENZINGER"

Double-Blind, Randomized, Placebo-Controlled Multi-Center Phase III Study Followed By Open-Label Phase on the Efficacy and Tolerability of Budesonide in Patients with Resistant Oral Chronic GVHD: Part 1 - Efficacy Analysis

Publikováno v: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 135:e42-e43

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e802438a2bbc12e8b010ea8512fbfd10
https://doi.org/10.1016/j.oooo.2022.09.028

Zobrazit plný text záznamu

Double-Blind, Randomized, Placebo-Controlled Multi-Center Phase III Study Followed by Open-Label Phase on the Efficacy and Tolerability of Budesonide in Patients with Resistant Oral Chronic GVHD: Part 2 – Pain, Subjective Measures and Safety Analysis

Publikováno v: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 135:e43-e44

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3512002eba18cffe54b1524f30d3c3a4
https://doi.org/10.1016/j.oooo.2022.09.029

Zobrazit plný text záznamu

Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan

Autor: Timothy P. Heffernan, Annette Machado, Ulrich Duenzinger, Joseph R. Marszalek, Christopher P. Vellano, Michael Gmachl, Mark Petronczki, Dorothea Rudolph, Daniel Gerlach, Marco H. Hofmann, Francesca Trapani, Vitomir Vucenovic, Norbert Kraut, Marcelo Marotti, Joseph R. Daniele, Irene Waizenegger, Hengyu Lu

Publikováno v: Cancer Research. 81:CT210-CT210

The SOS1i::KRAS inhibitor BI 1701963 is the first direct RAS signaling modifier to enter phase I clinical trials both as a monotherapy as well as in combination. SOS1::KRAS inhibitors exhibit activity against a broad spectrum of KRAS alleles, includi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5aba2ef95ed853c38d2a3066731e6927
https://doi.org/10.1158/1538-7445.am2021-ct210

Zobrazit plný text záznamu

Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients

Autor: Timo Wolf, Ulrich Duenzinger, Saskia Gueller, Hubert Serve, Sabine Mousset, Gesine Bug, Hans Martin, Salem Ajib, A. Berger

Publikováno v: Transplant infectious disease : an official journal of the Transplantation Society. 15(4)

Introduction Respiratory syncytial virus (RSV) is a frequent cause of respiratory tract infectious disease (RTID) in allogeneic hematopoietic stem cell transplant (HSCT) recipients associated with a high mortality once infection has progressed from u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f61683d755aa0f67d6eff481116e426
https://pubmed.ncbi.nlm.nih.gov/23692664

Zobrazit plný text záznamu

Post-Transplant Maintenance With The Deacetylase Inhibitor Panobinostat In Patients With High-Risk AML Or MDS: Results Of The Phase I Part Of The Panobest Trial

Autor: Gesine Bug, Andreas Burchert, Kroeger Nicolaus, Sabine Huenecke, Ulrich Duenzinger, Andrea Wolf, Peter Bader, Hubert Serve, Oliver G. Ottmann

Publikováno v: Blood. 122:3315-3315

Inhibitors of class I/II histone deacetylases (HDACi) possess anti-leukemic activity and have been reported to modulate the function of immune effector cells. Thus, they could provide specific clinical benefit in the allogeneic hematopoietic stem cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1800c29be36ba972a5feffd5bf92599a
https://doi.org/10.1182/blood.v122.21.3315.3315

Zobrazit plný text záznamu

Successful High-Dose Ribavirin Treatment of Respiratory Syncytial Virus-Induced Tracheobronchitis and Pneumonia Occuring Pre-Engraftment in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Autor: Sabine Mousset, Ulrich Duenzinger, Hans Martin, Gesine Bug, Timo Wolf, Saskia Gueller, Hubert Serve

Publikováno v: Blood. 114:1163-1163

Abstract 1163 Poster Board I-185 Introduction Respiratory syncytial viruses (RSV) frequently cause severe respiratory disease in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Within the first post-transplant month, progression of u

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::89f80ffae0f3fa80cf48465c4b11aa8e
https://doi.org/10.1182/blood.v114.22.1163.1163

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání